Metabolic Syndrome: From Mechanisms to Interventions covers all aspects of this complex and multifactorial disease, providing a cutting-edge understanding of the problem of MetS, with a particular focus on its prevention and clinical management. The book discusses practical implementable approaches to its reversal in clinical practice, encompassing the entire spectrum of MetS, from molecular understanding to clinical therapeutics and prevention. This book is a valuable resource for clinicians in multiple specialties, including endocrinologists, diabetologists, hepatologists, gynecologists and researchers in related fields who need a deep understanding of the full range of scientific and clinical aspects of metabolic syndrome.
1. Metabolic Syndrome - p. iii 2. Cover - p. iii 3. Title Page - p. iii 4. Copyright - p. iv 5. Table of Contents - p. iv 6. Dedication - p. v 7. Contributors - p. xxi 8. Foreword - p. xxvii 9. Chapter 1 Metabolic syndrome—A glance through the sands of time - p. 1 10. Chapter 2 Beyond the metabolic syndrome: Adverse influences of insulin resistance on the aging process - p. 7 11. Chapter 3 Intrauterine malnutrition and future risk of metabolic syndrome - p. 21 12. Chapter 4 Intervening at the stage of metabolic syndrome to prevent type 2 diabetes—Is it justified? - p. 35 13. Chapter 5 Dietary fats and their effects on metabolic syndrome and its components - p. 45 14. Chapter 6 Epidemiology of metabolic syndrome: global scenario - p. 59 15. Chapter 7 Epidemiology of metabolic syndrome in South and South-East Asia - p. 73 16. Chapter 8 Barker hypothesis and metabolic syndrome - p. 85 17. Chapter 9 Understanding the complexities of metabolic syndrome in First Nations Australians - p. 93 18. Chapter 10 Nutrition in the pathogenesis of metabolic syndrome: Roles of sugar, salt and fat - p. 105 19. Chapter 11 Vitamin D deficiency and metabolic syndrome—Is there a causality? - p. 119 20. Chapter 12 Role of inflammation in the pathogenesis of metabolic syndrome - p. 137 21. Chapter 13 Role of oxidative stress in the pathogenesis of metabolic syndrome - p. 143 22. Chapter 14 Mitochondrial dysfunction and metabolic syndrome - p. 157 23. Chapter 15 The entero-insular axis and metabolic syndrome - p. 173 24. Chapter 16 Type I interferons in metabolic syndrome - p. 187 25. Chapter 17 Role of circadian rhythms in metabolic syndrome - p. 199 26. Chapter 18 The role of genetic and epigenetic factors in familial clustering of metabolic syndrome - p. 219 27. Chapter 19 Endocrine disruptors in the pathogenesis of metabolic syndrome - p. 235 28. Chapter 20 Atherosclerotic cardiovascular disease in metabolic syndrome - p. 249 29. Chapter 21 Atherosclerosis is the outcome of adaptive complexity in the Arterial Endothelial Microenvironment - p. 259 30. Chapter 22 NAFLD, the hepatic manifestation of the metabolic syndrome - p. 279 31. Chapter 23 Obesity associated hypogonadism—a growing concern in metabolic syndrome - p. 293 32. Chapter 24 Sleep apnea—A cause or a consequence of metabolic syndrome? - p. 309 33. Chapter 25 Renal manifestations of metabolic syndrome: the link between obesity and chronic kidney disease - p. 319 34. Chapter 26 Metabolic syndrome and periodontitis: pathophysiologic links and clinical implications - p. 327 35. Chapter 27 Insulin resistance and risk of osteoporosis - p. 333 36. Chapter 28 Glucagon and the metabolic syndrome - p. 337 37. Chapter 29 Assessment of insulin resistance: From the bench to bedside - p. 351 38. Chapter 30 Role of exercise in the prevention and treatment of metabolic syndrome - p. 367 39. Chapter 31 Pharmacologic therapies in metabolic syndrome with special reference to non-alcoholic fatty liver disease - p. 383 40. Chapter 32 Role of newer anti-diabetes drugs in prediabetes: A systematic review - p. 393 41. Chapter 33 Management of insulin resistance in PCOS - p. 407 42. Chapter 34 The role of bariatric surgery in the management of metabolic syndrome - p. 415 43. Chapter 35 Anti-inflammatory interventions to mitigate the cardiovascular risk in metabolic syndrome - p. 421 44. Chapter 36 Management of new onset dysglycemia in transplant recipients - p. 439 45. Chapter 37 Management of lipid abnormalities in metabolic syndrome - p. 453 46. Chapter 38 Overview of metabolic syndrome in children and adolescents—an Indian perspective - p. 463 47. Chapter 39 Metabolic syndrome in children and adolescent: South Asian perspective - p. 471 48. Chapter 40 Inter-relationship between polycystic ovary syndrome and metabolic syndrome - p. 479 49. Chapter 41 Metabolic syndrome—definition - p. 493 50. Chapter 42 Metabolic syndrome and cancer risk - p. 499 51. Chapter 43 Obesity-mediated insulin resistance in target tissues: role of adiponectin, fetuin-A, and irisin - p. 511 52. Chapter 44 Gut microbiota and metabolic syndrome: What's new? - p. 527 53. Chapter 45 Metabolic syndrome and COVID-19: An unholy alliance - p. 543 54. Chapter 46 MicroRNA modulation in metabolic syndrome: A novel insight into cardiometabolic diseases - p. 555 55. Chapter 47 Role of artificial intelligence in tackling the metabolic syndrome pandemic - p. 575 56. Chapter 48 Glucose handling by the brain and its implication in metabolic syndrome - p. 585 57. Chapter 49 Hypoglycemia, insulin resistance, and cardiovascular disease: A possible link - p. 597 58. Chapter 50 Dietary interventions to combat obesity in metabolic syndrome - Role of time restricted eating - p. 609 59. Chapter 51 Systemic inflammation in psoriasis: Sequel of metabolic syndrome∗ - p. 621 60. Chapter 52 Abdominal obesity and adipose tissue depots: Focus on intra-abdominal versus subcutaneous adipose tissue depots in Asian Indians - p. 635 61. Chapter 53 The immediate and long-term metabolic implications of maternal obesity and gestational weight gain - p. 647 62. Chapter 54 Managing the metabolic syndrome in a general practice setting in the UK (by a general practitioner practising among a high risk South Asian population) - p. 657 63. Index - p. 661 64. Index - continued - p. 669
Metabolic Syndrome: From Mechanisms to Interventions covers all aspects of this complex and multifactorial disease, providing a cutting-edge understanding of the problem of MetS, with a particular focus on its prevention and clinical management. The book discusses practical implementable approaches to its reversal in clinical practice, encompassing the entire spectrum of MetS, from molecular understanding to clinical therapeutics and prevention. This book is a valuable resource for clinicians in multiple specialties, including endocrinologists, diabetologists, hepatologists, gynecologists and researchers in related fields who need a deep understanding of the full range of scientific and clinical aspects of metabolic syndrome.
1. Metabolic Syndrome - p. iii 2. Cover - p. iii 3. Title Page - p. iii 4. Copyright - p. iv 5. Table of Contents - p. iv 6. Dedication - p. v 7. Contributors - p. xxi 8. Foreword - p. xxvii 9. Chapter 1 Metabolic syndrome—A glance through the sands of time - p. 1 10. Chapter 2 Beyond the metabolic syndrome: Adverse influences of insulin resistance on the aging process - p. 7 11. Chapter 3 Intrauterine malnutrition and future risk of metabolic syndrome - p. 21 12. Chapter 4 Intervening at the stage of metabolic syndrome to prevent type 2 diabetes—Is it justified? - p. 35 13. Chapter 5 Dietary fats and their effects on metabolic syndrome and its components - p. 45 14. Chapter 6 Epidemiology of metabolic syndrome: global scenario - p. 59 15. Chapter 7 Epidemiology of metabolic syndrome in South and South-East Asia - p. 73 16. Chapter 8 Barker hypothesis and metabolic syndrome - p. 85 17. Chapter 9 Understanding the complexities of metabolic syndrome in First Nations Australians - p. 93 18. Chapter 10 Nutrition in the pathogenesis of metabolic syndrome: Roles of sugar, salt and fat - p. 105 19. Chapter 11 Vitamin D deficiency and metabolic syndrome—Is there a causality? - p. 119 20. Chapter 12 Role of inflammation in the pathogenesis of metabolic syndrome - p. 137 21. Chapter 13 Role of oxidative stress in the pathogenesis of metabolic syndrome - p. 143 22. Chapter 14 Mitochondrial dysfunction and metabolic syndrome - p. 157 23. Chapter 15 The entero-insular axis and metabolic syndrome - p. 173 24. Chapter 16 Type I interferons in metabolic syndrome - p. 187 25. Chapter 17 Role of circadian rhythms in metabolic syndrome - p. 199 26. Chapter 18 The role of genetic and epigenetic factors in familial clustering of metabolic syndrome - p. 219 27. Chapter 19 Endocrine disruptors in the pathogenesis of metabolic syndrome - p. 235 28. Chapter 20 Atherosclerotic cardiovascular disease in metabolic syndrome - p. 249 29. Chapter 21 Atherosclerosis is the outcome of adaptive complexity in the Arterial Endothelial Microenvironment - p. 259 30. Chapter 22 NAFLD, the hepatic manifestation of the metabolic syndrome - p. 279 31. Chapter 23 Obesity associated hypogonadism—a growing concern in metabolic syndrome - p. 293 32. Chapter 24 Sleep apnea—A cause or a consequence of metabolic syndrome? - p. 309 33. Chapter 25 Renal manifestations of metabolic syndrome: the link between obesity and chronic kidney disease - p. 319 34. Chapter 26 Metabolic syndrome and periodontitis: pathophysiologic links and clinical implications - p. 327 35. Chapter 27 Insulin resistance and risk of osteoporosis - p. 333 36. Chapter 28 Glucagon and the metabolic syndrome - p. 337 37. Chapter 29 Assessment of insulin resistance: From the bench to bedside - p. 351 38. Chapter 30 Role of exercise in the prevention and treatment of metabolic syndrome - p. 367 39. Chapter 31 Pharmacologic therapies in metabolic syndrome with special reference to non-alcoholic fatty liver disease - p. 383 40. Chapter 32 Role of newer anti-diabetes drugs in prediabetes: A systematic review - p. 393 41. Chapter 33 Management of insulin resistance in PCOS - p. 407 42. Chapter 34 The role of bariatric surgery in the management of metabolic syndrome - p. 415 43. Chapter 35 Anti-inflammatory interventions to mitigate the cardiovascular risk in metabolic syndrome - p. 421 44. Chapter 36 Management of new onset dysglycemia in transplant recipients - p. 439 45. Chapter 37 Management of lipid abnormalities in metabolic syndrome - p. 453 46. Chapter 38 Overview of metabolic syndrome in children and adolescents—an Indian perspective - p. 463 47. Chapter 39 Metabolic syndrome in children and adolescent: South Asian perspective - p. 471 48. Chapter 40 Inter-relationship between polycystic ovary syndrome and metabolic syndrome - p. 479 49. Chapter 41 Metabolic syndrome—definition - p. 493 50. Chapter 42 Metabolic syndrome and cancer risk - p. 499 51. Chapter 43 Obesity-mediated insulin resistance in target tissues: role of adiponectin, fetuin-A, and irisin - p. 511 52. Chapter 44 Gut microbiota and metabolic syndrome: What's new? - p. 527 53. Chapter 45 Metabolic syndrome and COVID-19: An unholy alliance - p. 543 54. Chapter 46 MicroRNA modulation in metabolic syndrome: A novel insight into cardiometabolic diseases - p. 555 55. Chapter 47 Role of artificial intelligence in tackling the metabolic syndrome pandemic - p. 575 56. Chapter 48 Glucose handling by the brain and its implication in metabolic syndrome - p. 585 57. Chapter 49 Hypoglycemia, insulin resistance, and cardiovascular disease: A possible link - p. 597 58. Chapter 50 Dietary interventions to combat obesity in metabolic syndrome - Role of time restricted eating - p. 609 59. Chapter 51 Systemic inflammation in psoriasis: Sequel of metabolic syndrome∗ - p. 621 60. Chapter 52 Abdominal obesity and adipose tissue depots: Focus on intra-abdominal versus subcutaneous adipose tissue depots in Asian Indians - p. 635 61. Chapter 53 The immediate and long-term metabolic implications of maternal obesity and gestational weight gain - p. 647 62. Chapter 54 Managing the metabolic syndrome in a general practice setting in the UK (by a general practitioner practising among a high risk South Asian population) - p. 657 63. Index - p. 661 64. Index - continued - p. 669
